Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS

The INTERCLIMA (Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria Identified by Optical Coherence Tomography in Patients With Acute Coronary Syndrome) is a multi-center, prospective, randomized trial of optical coherence tomography (OCT)-based versus physiology-based (i.e. fractional flow reserve[FFR]/instantaneous Wave-Free Ratio[iFR]/resting full-cycle ratio[RFR]) treatment of intermediate (40-70% diameter stenosis at …

stenosis
acute coronary syndrome
angiography
  • 0 views
  • 06 Sep, 2021
  • 1 location
OCT vs IVUS vs QCA to Guide Moderate-to-severe Calcified Lesion Stent Implantation

This study is a prospective, multi-center, randomized controlled clinical trial, aims to assess the safety and effectiveness of Optical Coherence Tomography or Intravascular Ultrasound or

  • 1 views
  • 19 Feb, 2022
  • 1 location
Coronary Rotational Atherectomy Elective vs. Bailout in Severely Calcified Lesions and Chronic Renal Failure (CRATER)

between rotational atherectomy and angioplasty alone in the setting of chronic renal failure and with intravascular ultrasound assessment for detecting severely calcified coronary arteries.

stenosis
percutaneous coronary intervention
myocardial infarction
infarct
intravascular ultrasound
  • 0 views
  • 12 May, 2022
  • 1 location
DEep VEin Lesion OPtimisation (DEVELOP) Trial (Develop)

to undergo either truncal ablation and compression therapy or truncal ablation, simultaneous iliac interrogation with intravascular ultrasound and stenting of significant (>50%) iliac vein lesions

Accepts healthy volunteers
compression therapy
healing ulcer
endovenous ablation
  • 7 views
  • 28 Feb, 2022
  • 2 locations
Predicting Pediatric Pulmonary Vein Stenosis Outcomes Using Data Acquired During a Cardiac Catheterization

), intravascular ultrasound (IVUS; pictures of the vein wall using a catheter inside the vein), pressure assessment and compliance testing. The status of each pulmonary vein will then be assessed 12 months after

stenosis
angiography
  • 0 views
  • 04 Oct, 2022
  • 1 location
Effect of Evolocumab on Coronary Plaque Characteristics (YELLOW III)

changes in (1) the maximal lipid arc, lipid length, lipid volume index, macrophage accumulation and calcification by OCT; (2) PAV and TAV defined by intravascular ultrasound (IVUS) and (3) Changes in

hmg-coa reductase inhibitors
stenosis
percutaneous coronary intervention
angiography
intravascular ultrasound
  • 0 views
  • 14 May, 2022
  • 1 location
IVUS Study for SV Graft: Y-composite vs Aortocoronary Conduit

conduit. Thus, we aimed to evaluate morphologic change of saphenous vein graft by 1-year intravascular ultrasound (IVUS) study and angiographic patency results between Y-composite graft and aortocoronary

intravascular ultrasound
bypass graft
  • 0 views
  • 04 Oct, 2022
  • 1 location
ANGiographic Evaluation of Left Main Coronary Artery INtErvention (ANGELINE)

To assess if an angiographic follow-up at 6 months after Percutaneous Coronary Intervention in Left Main Coronary Artery Disease decrease the composite objective of death, myocardial infarction, and stroke at 36 months.

percutaneous coronary intervention
angiography
stroke
infarct
everolimus
  • 0 views
  • 07 Jun, 2022
  • 30 locations
Usual Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque

The aim of this prospective, open-label, randomized, single center study is to compare the effect of usual dose rosuvastatin plus ezetimibe and high-dose rosuvastatin on modifying atherosclerotic plaque.

stenosis
heart disease
ezetimibe
intravascular ultrasound
rosuvastatin
  • 10 views
  • 18 Nov, 2021
  • 1 location
An Intravenous, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers

Background Heart disease is the leading cause of death, disability, and healthcare expense in the United States. Researchers think a new drug called Fx-5A may be useful to treat different cardiovascular diseases and inflammation. Objective To understand the safety, tolerability, and effects of Fx-5A. Eligibility Healthy people ages 18 and …

heart disease
Accepts healthy volunteers
  • 0 views
  • 21 Oct, 2022
  • 1 location